New insights into mechanism behind tuberous sclerosis complex tumors: December 5, 2014
Findings by Harvard School of Public Health’s Brendan Manning, professor of genetics and complex diseases, are providing new insights into tuberous sclerosis complex (TSC) — a rare genetic disease that causes the widespread growth of benign tumors — and may ultimately lead to treatment. His work characterizes the molecular mechanisms involved with the functional loss in one of two genes that ultimately leads to TSC tumors. (Link)
Dr. Manning promoted to Professor of Genetics & Complex Diseases: July 1, 2013
Dr. Manning’s research is focused on the interface between signaling and metabolic control under physiological and pathophysiological conditions. He is particularly interested in defining the control mechanisms and functions of a complex signaling network that is implicated in a diverse array of human diseases, including the majority of genetic tumor syndromes and cancers, metabolic diseases such as diabetes and cardiovascular disease, neurocognitive and neurodegenerative diseases such as autism and Alzheimer’s, and autoimmune diseases. As a postdoctoral fellow in the laboratory of Lewis Cantley, he found that the tumor suppressor TSC2 is the key molecular link between the PI3K and mTOR pathways. This finding helped connect a primary growth factor and insulin-stimulated pathway (PI3K), which is also activated in the majority of cancers, to a ubiquitous nutrient-sensing protein kinase that promotes cell growth (mTOR). Since that early landmark discovery, he has continued to make major contributions to our understanding of this key regulatory hub in mammalian cells and tissues, including the recognition that mTOR is a central player in the control of anabolic processes driving the synthesis of proteins, nucleic acids, and lipids. His laboratory’s findings are providing both underlying mechanisms and potential therapeutic strategies for common complex diseases, such as cancer and diabetes. In the future, Dr. Manning plans to expand his research to explore molecular events contributing to aging and autism spectrum disorders, other areas where this signaling network has been implicated.
Dr. Manning received his PhD in molecular, cellular, and developmental biology from Yale University in 2000. After completing his postdoctoral training in signal transduction, cell biology, and systems biology at Harvard Medical School, he was recruited to HSPH in 2004 as the first junior faculty member of the then newly established Department of Genetics and Complex Diseases. Dr. Manning is also affiliated with the research programs in cancer cell biology and kidney cancer at Dana Farber/Harvard Cancer Center.
Harvard Gazette: March 18, 2013
A new study by Harvard School of Public Health (HSPH) researchers is the first to identify the primary mechanism controlling a metabolic process essential for cell growth and proliferation. This pathway is centered around the mTOR protein, which relays growth signals to cells in response to external stimuli, including insulin and nutrients. The scientists speculate that one day researchers may be able to use this new knowledge to develop treatments for certain cancers which have uncontrolled mTOR signaling.
The study appeared online in the February 21, 2013 issue of Science Express.
Metabolic Changes in Cancer Webinar: April 19, 2012
Please visit http://webinar.sciencemag.org/webinar/archive/metabolic-changes-cancer to view this seminar.
HSPH News: March 1, 2011